From GlobeNewswire: 2024-05-16 01:27:00

Pharma Equity Group’s Q1-24 report covers January to March 2024, with a net loss of DKK 7.2 million. Clinical results from Reponex show positive outcomes for RNX-051 treatment in right-sided colon cancer patients. Patents for innovative treatments like RNX-051 for colorectal cancer have been approved. A Market Maker agreement with Danske Bank has been signed.

Reponex’s MEFO study focuses on treating right-sided colon cancer with RNX-051. Financially, Pharma Equity Group expects a pre-tax loss of DKK 24-29 million for 2024. They aim to boost working capital through a capital increase. Success in recovering EUR 9.55 million from Portinho S.A. remains uncertain despite legal action.

Pharma Equity Group maintains support for Reponex Pharmaceuticals’ development. They aim to enhance drug candidates and explore potential investments. Capital resources have been secured through convertible loans. An extraordinary general meeting is planned for June 3, 2024, to address capital reduction proposals.

CEO Thomas Kaas Selsø will present the Q1-24 report and key events live online. Questions can be directed to investor relations. The company’s focus on healthcare innovation drives its collaboration with Reponex Pharmaceuticals. Future investments are also being considered to further growth and development.



Read more at GlobeNewswire:: Konsolideret delårsrapport 1. januar – 31. marts 2024